	US 12,303,523 B2
	Method for treating dupuytren's disease
Anton Leighton, Oakland, CA (US); and Ralph T. Salvagno, Hancock, MD (US)
Assigned to DALE BIOTECH, LLC, Oakland, CA (US)
Filed by Dale Biotech, LLC, Kennedale, TX (US)
Filed on Dec. 3, 2021, as Appl. No. 17/457,524.
Application 17/457,524 is a continuation of application No. PCT/US2020/036405, filed on Jun. 5, 2020.
Claims priority of provisional application 62/858,752, filed on Jun. 7, 2019.
Prior Publication US 2022/0088047 A1, Mar. 24, 2022
Int. Cl. A61K 31/7028 (2006.01); A61K 31/609 (2006.01); A61P 19/02 (2006.01)

CPC A61K 31/7028 (2013.01) [A61K 31/609 (2013.01); A61P 19/02 (2018.01)]

8 Claims

1. A method for treating Dupuytren's disease, osteoarthritis, or adhesive capsulitis, comprising administering to a patient in need thereof an effective amount of one or more rhamnolipids, wherein the rhamnolipids are selected from the group consisting of: α-L-rhamnosyl-β-hydroxydecanoyl-β-hydroxydecanoate, α-L-rhamnosyl-(1-2)-α-L-rhamnosyl-β-hydroxydecanoyl-β-hydroxydecanoate, α-L-rhamnopyranosyl-(1,2)-α-L-rhamnopyranosyl-β-hydroxydecanoyl-β-hydroxydodecanoate; α-L-rhamnopyranosyl-(1,2)-α-L-rhamnopyranosyl-β-hydroxytetradecanoyl-β-hydroxytetradecanoate, and a combination thereof.